Mouse models of thyroid cancer: Bridging pathogenesis and novel therapeutics

Jin, Yuchen; Liu, Min; Sa, Ri; Fu, Hao; Cheng, Lin; Chen, Libo

doi:10.1016/j.canlet.2019.09.017

Cited by 17 publications

(20 citation statements)

References 244 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PI3K/Akt pathway is one of the most important pathways regulating cell proliferation, apoptosis, and cell cycle in multiple cancer cells, including HCC [ 33 – 35 ]. High expression and aberrant increase of action of PI3K pathways have been widely documented in multiple human cancers [ 36 ].…”

Section: Discussionmentioning

confidence: 99%

Asiaticoside Antagonizes Proliferation and Chemotherapeutic Drug Resistance in Hepatocellular Carcinoma (HCC) Cells

Wen

Wang

et al. 2020

Med Sci Monit

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Asiaticoside Antagonizes Proliferation and Chemotherapeutic Drug Resistance in Hepatocellular Carcinoma (HCC) Cells

Wen

Wang

et al. 2020

Med Sci Monit

View full text Add to dashboard Cite

“…A375 cells suspended in sterile PBS and matrigel matrix (Corning) with a ratio of 1:1 were used to establish subcutaneous melanoma models [19]. We have reported that the ATC cell line THJ-16T has a tumor take rate as high as 100% in athymic nude mice [20], and orthotopic thyroid cancer models better mirror the aggressive scenario of advanced thyroid cancers [21,22]. Therefore, we chose the THJ-16T cell line and the ultra-immunodeficient R2G2 (B6;129-Rag2 tm1Fwa IL2rg tm1Rsky /DwlHsd; Envigo) mice to establish thyroid cancer models.…”

Section: Melanoma and Thyroid Cancer Modelsmentioning

confidence: 99%

Development and characterization of CD54-targeted immunoPET imaging in solid tumors

Wei

Jiang

Lee

et al. 2020

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose-Intercellular adhesion molecule-1 (ICAM-1, CD54) is an emerging therapeutic target for a variety of solid tumors including melanoma and anaplastic thyroid cancer (ATC). This study aims to develop an ICAM-1-targeted immuno-positron emission tomography (immunoPET) imaging strategy and assess its diagnostic value in melanoma and ATC models.Methods-Flow cytometry was used to screen ICAM-1-positive melanoma and ATC cell lines. Melanoma and ATC models were established using A375 cell line and THJ-16T cell line, respectively. An ICAM-1-specific monoclonal antibody (R6-5-D6) and a nonspecific human IgG were radiolabeled with 64 Cu and the diagnostic efficacies were interrogated in tumor-bearing mouse models. Biodistribution and fluorescent imaging studies were performed to confirm the specificity of the ICAM-1-targeted imaging probes.Results-ICAM-1 was strongly expressed on melanoma and advanced thyroid cancer cell lines. 64 Cu-NOTA-ICAM-1 immunoPET imaging efficiently delineated A375 melanomas with a peak tumor uptake of 21.28 ± 6.56 %ID/g (n = 5), significantly higher than that of 64 Cu-NOTA-IgG (10.63 ± 2.58 %ID/g, n = 3). Moreover, immunoPET imaging with 64 Cu-NOTA-ICAM-1 efficiently visualized subcutaneous and orthotopic ATCs with high clarity and contrast.

show abstract

“…Ras protein is a classical molecular switch, turning between off and on states during signal transduction. RAS gene mutation abrogates its switching capacity leaving it in a constitutively active state, promoting diseased conditions ( 38 , 39 ). It has been shown that the Ras signaling pathway plays significant roles in cellular differentiation, proliferation, apoptosis, and carcinogenesis ( 38 – 40 ).…”

Section: Discussionmentioning

confidence: 99%

Construction of a Signature Model to Predict the Radioactive Iodine Response of Papillary Thyroid Cancer

et al. 2022

View full text Add to dashboard Cite

Papillary thyroid cancer (PTC) accounts for about 90% of thyroid cancer. There are approximately 20%–30% of PTC patients showing disease persistence/recurrence and resistance to radioactive iodine (RAI) treatment. For these PTC patients with RAI refractoriness, the prognosis is poor. In this study, we aimed to establish a comprehensive prognostic model covering multiple signatures to increase the predictive accuracy for progression-free survival (PFS) of PTC patients with RAI treatment. The expression profiles of mRNAs and miRNAs as well as the clinical information of PTC patients were extracted from TCGA and GEO databases. A series of bioinformatics methods were successfully applied to filtrate a two-RNA model (IPCEF1 and hsa-mir-486-5p) associated with the prognosis of RAI-therapy. Finally, the RNA-based risk score was calculated based on the Cox coefficient of the individual RNA, which achieved good performances by the time-dependent receiver operating characteristic (tROC) curve and PFS analyses. Furthermore, the predictive power of the nomogram, integrated with the risk score and clinical parameters (age at diagnosis and tumor stage), was assessed by tROC curves. Collectively, our study demonstrated high precision in predicting the RAI response of PTC patients.

show abstract

Mouse models of thyroid cancer: Bridging pathogenesis and novel therapeutics

Cited by 17 publications

References 244 publications

Asiaticoside Antagonizes Proliferation and Chemotherapeutic Drug Resistance in Hepatocellular Carcinoma (HCC) Cells

Asiaticoside Antagonizes Proliferation and Chemotherapeutic Drug Resistance in Hepatocellular Carcinoma (HCC) Cells

Development and characterization of CD54-targeted immunoPET imaging in solid tumors

Construction of a Signature Model to Predict the Radioactive Iodine Response of Papillary Thyroid Cancer

Contact Info

Product

Resources

About